Edition:
United Kingdom

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

0.63USD
9:00pm BST
Change (% chg)

$-0.09 (-12.97%)
Prev Close
$0.72
Open
$0.71
Day's High
$0.71
Day's Low
$0.62
Volume
47,006
Avg. Vol
141,171
52-wk High
$1.51
52-wk Low
$0.49

Chart for

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $50.18
Shares Outstanding(Mil.): 28.67
Dividend: --
Yield (%): --

Financials

  GNCA.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -2.04 -- --
ROI: -97.45 0.21 14.27
ROE: -127.17 1.17 15.99

BRIEF-Genocea Biosciences Files For Mixed Shelf Of Up To $200 Mln

* GENOCEA BIOSCIENCES INC - FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (https://bit.ly/2GBQyfr) Further company coverage:

21 May 2018

BRIEF-Genocea Reports Qtrly Loss Per Share $0.21

* GENOCEA REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

10 May 2018

BRIEF-Genocea Biosciences Enters Into Term Loan Facility Of $14 Million With Hercules

* GENOCEA BIOSCIENCES INC - ON APRIL 24, CO ENTERED INTO TERM LOAN FACILITY OF $14 MILLION WITH HERCULES

01 May 2018

BRIEF-Genocea Files IND For Neoantigen Cancer Vaccine Candidate Gen-009

* GENOCEA - FILES IND FOR NEOANTIGEN CANCER VACCINE CANDIDATE GEN-009, PLANS TO INITIATE PHASE 1/2A CLINICAL PROGRAM LATER THIS YEAR

30 Apr 2018

Earnings vs. Estimates